Breaking Finance News

Orthofix International NV (NASDAQ:OFIX) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $42.01, Orthofix International NV (NASDAQ:OFIX) traded -1.78% lower on the day. With the last close down -4.18% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Orthofix International NV has recorded a 50-day average of $43.84 and a two hundred day average of $43.84. Volume of trade was down over the average, with 81,744 shares of OFIX changing hands under the typical 106,050

Zacks Investment Research has downgraded Orthofix International NV (NASDAQ:OFIX) to Hold in a statement released on Tuesday October 04, 2016.

Recent Performance Chart

Orthofix International NV (NASDAQ:OFIX)

Orthofix International NV has 52 week low of $32.25 and a 52 week high of $48.25 and has a market capitalization of $0.

Brief Synopsis On Orthofix International NV (NASDAQ:OFIX)

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim. Its Biologic solutions products include AlloQuent Structural Allografts, Trinity ELITE, Trinity Evolution, VersaShield and Collage Synthetic Osteoconductive Scaffold. Its Extremity Fixation solutions include Fixator, TrueLok, TL-HEX TrueLok Hexapod System, PREFIX and PREFIX 2, Centronail Titanium Nailing System and Galaxy Fixation System. Its Spine Fixation solutions products include Ascent LE Posterior Occipital Cervico-Thoracic (POCT) System, ATHLET Vertebral Body Replacement (VBR) System, NGage Surgical Mesh System and PILLAR AL PEEK Partial VBR System.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *